Technical Analysis for CYCC - Cyclacel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 0.76 20.92% 0.13
CYCC closed up 20.92 percent on Friday, May 24, 2019, on 25.29 times normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical CYCC trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
New Uptrend Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Lower Bollinger Band Walk Weakness 0.00%

Older signals for CYCC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Serious Diseases Autoimmune And Inflammatory Diseases Cyclacel Treatment Of Autoimmune And Inflammatory Diseases Dna Synthesis PLK1 Cdk Inhibitor Cell Cycle Cell Cycle Checkpoint Cyclin Dependent Kinase Cyclin Dependent Kinase 2 E Human Cancers M Checkpoint Sapacitabine Seliciclib
Is CYCC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.87
52 Week Low 0.51
Average Volume 1,104,299
200-Day Moving Average 1.0057
50-Day Moving Average 0.7765
20-Day Moving Average 0.696
10-Day Moving Average 0.6754
Average True Range 0.0718
ADX 29.14
+DI 42.2342
-DI 13.5902
Chandelier Exit (Long, 3 ATRs ) 0.8046
Chandelier Exit (Short, 3 ATRs ) 0.8254
Upper Bollinger Band 0.7666
Lower Bollinger Band 0.6254
Percent B (%b) 0.95
BandWidth 20.287356
MACD Line -0.0237
MACD Signal Line -0.0289
MACD Histogram 0.0052
Fundamentals Value
Market Cap 8.66 Million
Num Shares 11.4 Million
EPS -4.18
Price-to-Earnings (P/E) Ratio -0.18
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.24
Resistance 3 (R3) 1.27 1.15 1.16
Resistance 2 (R2) 1.15 1.02 1.13 1.13
Resistance 1 (R1) 0.95 0.95 0.89 0.92 1.11
Pivot Point 0.83 0.83 0.80 0.81 0.83
Support 1 (S1) 0.63 0.70 0.57 0.60 0.41
Support 2 (S2) 0.51 0.63 0.49 0.39
Support 3 (S3) 0.31 0.51 0.36
Support 4 (S4) 0.28